Save time and get answers to complex questions with AI chat
Generic brand for latisse?Does lipitor's effectiveness decrease with high fat meals?Mebendazole 100mg price?What are the most memorable drug brands in oral factor b inhibitors? in united statesPramlintide acetate price?
See the DrugPatentWatch profile for lurbinectedin
Lurbinectedin is a chemotherapeutic agent that has been explored in combination with immunotherapies to enhance its anti-tumor effects. According to a study published in the Journal of Clinical Oncology 1, lurbinectedin has been combined with pembrolizumab, a PD-1 checkpoint inhibitor. In preclinical studies, this combination demonstrated synergistic anti-tumor activity in various cancer models, indicating potential for clinical use. Additionally, lurbinectedin has been investigated in combination with atezolizumab, another PD-L1 checkpoint inhibitor 2, and talabotulinumab, a TRAIL receptor agonist 3. These studies aim to determine whether adding immunotherapy to lurbinectedin can enhance treatment efficacy and overcome resistance to single-agent therapy. Sources: [1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7324418/ [2] https://pubmed.ncbi.nlm.nih.gov/32744134/ [3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8131425/
Other Questions About Lurbinectedin :